Hugel, Inc. (145020.KQ)
| Previous close | 199,900.00 |
| Open | 199,900.00 |
| Bid | 200,500.00 x 0 |
| Ask | 202,500.00 x 0 |
| Day's range | 198,100.00 - 203,500.00 |
| 52-week range | 99,700.00 - 219,000.00 |
| Volume | |
| Avg. volume | 55,448 |
| Market cap | 2.28T |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Hugel Receives U.S. FDA Approval for Its Botulinum Toxin Letybo
Hugel, a global total medical aesthetics company, announced that the company has received marketing approval from the U.S. Food and Drug Administration(FDA) on the 29th(local time) for 50 units and 100 units of its botulinum toxin Letybo.
- PR Newswire
Hugel Achieves Record-High Revenue and Operating Profit
Hugel, a global total medical aesthetics company, announced its 4Q 23 consolidated financial results on the 14th, reporting revenue of KRW 88.9 billion, operating profit of KRW 36.8 billion, and net profit of KRW 17.1billion, achieving another quarterly record-high. Sales revenue, operating profit, and net profit grew by 4%, 22.4%, and 451.6%, respectively, YoY.
- PR Newswire
Hugel Breaks 3Q Quarterly and Cumulative Earnings Record
Hugel, a global total medical aesthetics company, announced its 3Q 23 consolidated financial results on the 13th, reporting revenue of KRW 84.8 billion, operating profit of KRW 34.6 billion, and net profit of KRW 41.6 billion.
